1. Home
  2. SNDX vs FLYW Comparison

SNDX vs FLYW Comparison

Compare SNDX & FLYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • FLYW
  • Stock Information
  • Founded
  • SNDX 2005
  • FLYW 2009
  • Country
  • SNDX United States
  • FLYW United States
  • Employees
  • SNDX N/A
  • FLYW N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • FLYW Computer Software: Prepackaged Software
  • Sector
  • SNDX Health Care
  • FLYW Technology
  • Exchange
  • SNDX Nasdaq
  • FLYW Nasdaq
  • Market Cap
  • SNDX 1.1B
  • FLYW 1.1B
  • IPO Year
  • SNDX 2016
  • FLYW 2021
  • Fundamental
  • Price
  • SNDX $10.70
  • FLYW $10.89
  • Analyst Decision
  • SNDX Strong Buy
  • FLYW Buy
  • Analyst Count
  • SNDX 11
  • FLYW 16
  • Target Price
  • SNDX $35.91
  • FLYW $17.71
  • AVG Volume (30 Days)
  • SNDX 2.3M
  • FLYW 3.0M
  • Earning Date
  • SNDX 05-05-2025
  • FLYW 05-06-2025
  • Dividend Yield
  • SNDX N/A
  • FLYW N/A
  • EPS Growth
  • SNDX N/A
  • FLYW N/A
  • EPS
  • SNDX N/A
  • FLYW 0.04
  • Revenue
  • SNDX $43,722,000.00
  • FLYW $511,493,000.00
  • Revenue This Year
  • SNDX $263.44
  • FLYW $13.82
  • Revenue Next Year
  • SNDX $129.44
  • FLYW $16.22
  • P/E Ratio
  • SNDX N/A
  • FLYW $306.15
  • Revenue Growth
  • SNDX N/A
  • FLYW 20.97
  • 52 Week Low
  • SNDX $9.66
  • FLYW $8.20
  • 52 Week High
  • SNDX $25.07
  • FLYW $23.40
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 38.98
  • FLYW 66.25
  • Support Level
  • SNDX $9.67
  • FLYW $9.50
  • Resistance Level
  • SNDX $14.24
  • FLYW $11.43
  • Average True Range (ATR)
  • SNDX 0.93
  • FLYW 0.41
  • MACD
  • SNDX -0.26
  • FLYW 0.34
  • Stochastic Oscillator
  • SNDX 22.62
  • FLYW 81.31

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

Share on Social Networks: